Merck & Co's New Shingles Vaccine Clears First Phase III Hurdle

Merck & Co has positive data from the first of two Phase III trials of its new varicella zoster virus vaccine for the prevention of shingles in immunocompromised patients, but will the product be enough to prop up its waning Zostavax in the face of GSK's Shingrix?